Postpolypectomy Colonoscopy Surveillance Guidelines: Predictive Accuracy for Advanced Adenoma at 4 Years
A. Laiyemo,G. Murphy,P. Albert,L. Sansbury,Zhuoqiao Wang,A. Cross,P. Marcus,B. Caan,J. Marshall,P. Lance,E. Paskett,J. Weissfeld,M. Slattery,R. Burt,F. Iber
DOI: https://doi.org/10.7326/0003-4819-148-6-200803180-00004
IF: 39.2
2008-03-18
Annals of Internal Medicine
Abstract:Context Guidelines for surveillance colonoscopy after removing a colon polyp recommend more frequent surveillance after a high-risk finding at baseline (an advanced adenoma or 3 adenomas). Contribution The authors studied 1905 patients who had an adenoma at baseline colonoscopy and had follow-up colonoscopy at 1 year and 4 years. Overall, 6.6% had an advanced adenomaconsidered to be high risk to become malignantat 4 years. The advanced adenoma rates were 9% and 5% in patients with high-risk and low-risk adenomas at baseline colonoscopy, respectively. Implication The characteristics of an adenoma are not a reliable guide to the probability of recurrence of an advanced adenoma. The Editors Clinical practice guidelines for postpolypectomy colonoscopy surveillance have been developed by different professional societies and updated as necessary on the basis of scientific evidence (14). However, surveys of gastrointestinal endoscopists (5) and primary care physicians (6, 7) have consistently shown a lack of adherence to surveillance guidelines, with repeated examinations being recommended at shorter intervals than the guidelines indicate. This suggests an overuse of surveillance colonoscopy, which already constitutes approximately 24% of procedures performed in the United States (8). Nonadherence may be due to a lack of knowledge of the guidelines, medical liability concerns, financial incentives, and differing recommendations by professional societies. The U.S. Multi-Society Task Force on Colorectal Cancer and the American Cancer Society jointly developed and published a consensus update for postpolypectomy surveillance guidelines in 2006 to provide more consistency among guidelines (9). Patients were stratified as having high risk or low risk for subsequent development of advanced neoplasia on the basis of adenoma characteristics at baseline. The guidelines classify patients with 3 or more synchronous adenomas or any advanced adenomas (adenomas 1 cm in diameter or with a villous histology or high-grade dysplasia) as high risk. Individuals found to be at high risk at baseline are to have follow-up colonoscopy in 3 years, whereas those with fewer, nonadvanced, adenomatous polyps (low-risk patients) are to have repeated examination in 5 to 10 years. The guidelines recommend 10-year follow-up evaluation for average-risk individuals (those with no adenomatous polyps). Lack of confidence in the postpolypectomy guidelines may be a common reason for nonadherence. According to Mysliwiec and colleagues (5), approximately 80% of surveyed endoscopists indicated that published evidence was very influential in their practice, but only half the respondents indicated that practice guidelines were very influential. This response highlights a perceived disconnect between published evidence and postpolypectomy guidelines. In another survey, 17% to 21% of gastroenterologists knew the guidelines but disregarded them, opting for earlier surveillance colonoscopy (10). Merritt and colleagues (11) reported that clinical practice guidelines are often fast-tracked without an adequate evaluation of their effectiveness. Therefore, validating guidelines may increase physicians' confidence and improve adherence. Our study is a step in that direction. We sought to assess the utility of the risk-based stratification recommended by the current guidelines, using data from the dietary PPT (Polyp Prevention Trial). We measured the ability of adenoma characteristics at baseline (as defined in the 2006 consensus update on postpolypectomy surveillance guidelines) to predict subsequent advanced adenoma recurrence within 4 years. Methods The Polyp Prevention Trial The rationale, design, and results of the PPT are published elsewhere (1214). In brief, the PPT was a 4-year, multicenter, randomized, controlled trial involving 2079 patients age 35 years or older who had at least 1 histologically confirmed adenoma removed during a screening or diagnostic colonoscopy within 6 months of random assignment. A total of 1663 patients reported a single reason for colonoscopy, whereas 416 had 2 or more reasons for the examination (12). Overall, approximately 9% had colonoscopy because of family history of polyps or cancer (screening), 22% for routine polyp surveillance, and 69% for diagnostic studies. The PPT sought to determine whether a low-fat, high-fiber diet affected the rate of colorectal adenoma recurrence. Patients were randomly assigned to adopt a low-fat, high-fiber diet with increased intake of fruits and vegetables or their usual diet (control). Exclusion criteria included a history of surgical resection of adenomatous polyps, bowel resection, colorectal carcinoma, the polyposis syndrome, or inflammatory bowel disease; use of lipid-lowering drugs; and body weight greater than 150% of ideal. The PPT was approved by the institutional review boards of the National Cancer Institute and each of the 8 participating clinical centers. All patients gave written informed consent. Our analysis is based on 1905 patients who completed the trial by having end point colonoscopy. The trial took place from 1991 to 1998. We included all patients in the trial because the dietary intervention had no effect on adenoma recurrence (14). Exposure and Outcome Assessment At baseline and at every annual follow-up visit, the investigators used direct interview to obtain information on each patient's demographic characteristics, health-related lifestyle, diet, and use of medication and dietary supplements. The patients had a clearing colonoscopy approximately 1 year after random assignment (1-year colonoscopy) to remove any lesion that the baseline colonoscopy missed. Patients were followed for approximately 4 years after random assignment and had a surveillance colonoscopy at the end of follow-up (4-year colonoscopy). We defined any histologically confirmed adenoma detected on colonoscopy after the 1-year colonoscopy as recurrent. For the 137 patients who did not have 1-year colonoscopy, we defined any histologically confirmed adenomatous polyps occurring at least 2 years after randomization as recurrent. We used the endoscopists' colonoscopy reports as the source for size, number, and location of polyps. Histology and degree of atypia were confirmed by 2 trial pathologists who were masked to the randomization. We defined adenomas removed from the rectosigmoid to the splenic flexure as distal and those removed from the transverse colon to cecum as proximal. Statistical Analysis We examined adenoma characteristics at baseline as predictors of advanced adenoma recurrence for up to 3 years after clearance colonoscopy as our primary analysis, similar to that of van Stolk and colleagues (15). We repeated our analyses after including adenomas found during clearance colonoscopy, as well as the recurrent adenomas defined above, even though the National Polyp Study (16) has reported that surveillance colonoscopy at 3 years was as effective as follow-up colonoscopy at both 1 and 3 years. We used SAS software (SAS Institute, Cary, North Carolina) for all analyses. We compared the baseline characteristics by using the t test and chi-square tests for continuous and categorical variables, respectively. We used log-binomial modeling (a binary regression model in which the probability of a recurrence is parameterized on the log scale) to assess baseline adenoma characteristics, as defined by the guidelines, as predictors of advanced adenomas through 4-year colonoscopy. This modeling method expresses association in terms of relative risks and 95% CIs. When the model did not converge, which is known to occur with log-binomial modeling, we used the SAS nonlinear programming procedure to find the maximum likelihood estimates (17). We used a Wald test to test whether the relative risks were equal to 1. We included age, sex, body mass index, nonsteroidal anti-inflammatory drug use, location of adenomas, and family history of colorectal cancer in the multivariable models. We calculated the probability of advanced adenoma recurrence as a function of baseline adenoma characteristics; this is mathematically equivalent to the positive predictive value associated with the baseline characteristics. We used the c-statistic (equivalent to the area under the receiver-operating characteristic curve) to measure discrimination (the ability of the predictive model to distinguish between patients with and those without the outcome of interest) (18, 19). The c-statistic is 0.5 if a prediction is no better than random and 1.0 for a perfectly predictive model. Comparison Groups for Analyses For all analyses of outcome, we compared recurrence of advanced adenomas versus no recurrence of advanced adenomas and versus no adenoma recurrence. We stratified baseline adenomas by size (1 cm vs. <1 cm in diameter), number (2 vs. 3 adenomas, and 1, 2, or 3 adenomas), degree of atypia (presence or absence of high-grade dysplasia), histology (villous or tubulovillous vs. no villous characteristics), advanced versus nonadvanced, and high-risk versus low-risk at baseline. We evaluated baseline adenoma location as distal only, proximal only, both proximal and distal, and unspecified. We excluded 41 patients from analyses involving adenoma location because the location could not be determined. Because we were interested in whether the presence of any proximal adenoma is associated with advanced adenoma recurrence, we analyzed baseline adenoma location by comparing any proximal adenoma (proximal only and both) with distal only. In another analysis of the risk associated with adenoma location, we included only patients with baseline low-risk adenomas (1 or 2 nonadvanced adenomas) and categorized them as having 1 distal, 1 proximal, 2 distal, or 2 adenomas (with at least 1 proximal adenoma). Role of the Funding Source The study was funded by the Intramural Research Program of the Center for Cancer Research and Division of Cancer Epidemiology